Clinical Trials Logo

Clinical Trial Summary

The aim is to elucidate how NO works in conjunction with other neurotransmitters to regulate the migrating motility complex (MMC). Twenty-two healthy volunteers should undergo water-perfused antroduodenojejunal manometry during a control period of 4 h, followed by another 4h after a bolus injection of either saline or the NO synthase inhibitor NG-monomethyl-L-arginine (L-NMMA, 10 mg/kg intravenously) with or without atropine (1 mg) or ondansetron (8 mg). Effects on the MMC pattern are determined. Exhaled and rectal NO is monitored throughout the experiments. Effects of L-NMMA on the MMC pattern are analyzed against a background of atropine or ondansetron. Blood samples are drawn for analysis of simultaneous peptide hormone release into the bloodstream. Peptide hormone release will be correlated to the respective motility pattern elicited by LNMMA.


Clinical Trial Description

Dysregulation of the cyclic motility pattern controlling propulsion during fasting, the migrating motor complex (MMC), can result in small intestinal bacterial overgrowth and symptoms of intestinal obstruction. Nitric oxide (NO) acts as an inhibitory neurotransmitter by relaxation of smooth muscle cells. Little is known on how NO works in conjunction with other neurotransmitters to regulate the MMC.

Methods: Twenty-two healthy volunteers (22-38 years) should undergo antroduodenojejunal manometry recordings for 8h, 4h of which as a control period with basal motility recording and 4h after a bolus injection of either saline or the NO synthase inhibitor NG-monomethyl-L-arginine (L-NMMA, 10 mg/kg intravenously) with or without atropine (1 mg) or ondansetron (8 mg). The effects of L-NMMA on the MMC pattern are to be determined. Exhaled and rectal NO was monitored throughout the experiments as a means to secure efficient NO synthase inhibition.

Expected results: L-NMMA is expected to increase the intestinal motor activity, either as a direct effect on the small muscle cells, or through the release of some motility-stimulating gut peptide hormone (motility, ghrelin, somatostatin).

Expected conclusions: A NO donor, such as nitrite or nitrate which is converted to NO in an acidic milieu in the stomach may act as an inhibitor of motility. Thus, swallowed nitrite and nitrate from the saliva may contribute to the regulation of gastric emptying and gastrointestinal motility. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science


Related Conditions & MeSH terms

  • Disturbance of Salivary Secretion
  • Gastrointestinal Motility Disorder

NCT number NCT02245165
Study type Interventional
Source Uppsala University
Contact
Status Completed
Phase Phase 1
Start date June 2013
Completion date May 2014

See also
  Status Clinical Trial Phase
Completed NCT04429802 - The Effect of Prucalopride (Resolor®) on Gastric Motor Function and Gastric Sensitivity N/A
Completed NCT01644240 - A Phase 1, Multiple Intravenous Dose Study to Examine the Safety, Tolerability, and Pharmacokinetics of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects Phase 1
Withdrawn NCT04244877 - Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility Phase 3
Terminated NCT02573519 - Gastrointestinal Motility Among Diabetes Patients N/A
Recruiting NCT04764019 - Intestinal Dysmotility in Patients With Functional Digestive Symptoms N/A
Completed NCT03012594 - Lanreotide in the Treatment of Small Bowel Motility Disorders Phase 2
Not yet recruiting NCT05268328 - The Effect of Foot Reflexology After Cesarean Section
Completed NCT03552510 - Oropharyngeal Administration of Mother's Milk in Preterm Infants and Gastrointestinal Motility N/A
Completed NCT01394055 - Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis Phase 1
Active, not recruiting NCT00793195 - Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants? Phase 2
Recruiting NCT04208828 - IVIG for Drug and Device Refractory Gastrointestinal Auto-Immune Neuropathy
Active, not recruiting NCT06347367 - Short-term Effect of Exercise and Self-manual Approaches to Bloating - Distention N/A
Recruiting NCT05989763 - Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis N/A
Recruiting NCT04988438 - Gastrointestinal Motor Disorders (Esophageal and Anorectal) After COVID-19
Completed NCT01635608 - Absorption of Paracetamol, Talinolol and Amoxicillin After Oral Administration Using Non-caloric and Caloric Water Phase 1